Jay Amin, MD
Cardiovascular Disease · Clearwater, FLNPI 1720077365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,200 of the $6,408 with a category attached, or 65.5%. AstraZeneca accounts for 74.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $2,134 and has fallen 71.6% since, to $606 in 2025.
Across 90 payments — averaging $71.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Medtronic$319
- Boston Scientific$244
- E.r. Squibb & Sons, L.L.C.$175
- Amgen$171
- Pfizer$137
- plus $567 from 14 others
Across 124 payments — averaging $6817.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$260K
- Janssen Research & Development, LLC$243K
- Eli Lilly$173K
- Kowa Research Institute, Inc.$63K
- AstraZeneca$52K
- Merck$41K
- plus $14K from 1 others
What the payments were for
- Speaking & faculty fees$4,20066%
- Travel & lodging$280%
- Food & beverage$2,17134%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $4,795 |
| Medtronic | 12 | $319 |
| Boston Scientific | 8 | $244 |
| E.r. Squibb & Sons, L.L.C. | 5 | $175 |
| Amgen | 11 | $171 |
| Pfizer | 5 | $137 |
| Johnson & Johnson | 4 | $73 |
| Axonics, Inc. | 1 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $58 |
| Abbott | 2 | $50 |
| Astellas Pharma US Inc | 2 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Novartis | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Millicent US Inc | 1 | $20 |
| Heartflow, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$4,447
- INTERSTIM$149
- WATCHMAN Access System$100
How this compares
$6,408 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $423,628 |
| XareltoRivaroxaban | 126 | $142,942 |
| EntrestoSacubitril/Valsartan | 119 | $142,732 |
| Repatha SureclickEvolocumab | 47 | $49,280 |
| FarxigaDapagliflozin Propanediol | 20 | $24,148 |
| BrilintaTicagrelor | 21 | $22,798 |
| Dofetilide | 13 | $8,917 |
| VascepaIcosapent Ethyl | 22 | $7,614 |
| Rosuvastatin Calcium | 373 | $5,740 |
| Metoprolol Succinate | 317 | $4,456 |
| Flecainide Acetate | 105 | $4,378 |
| Atorvastatin Calcium | 316 | $4,014 |
| Amiodarone Hcl | 90 | $2,973 |
| Amlodipine Besylate | 457 | $2,889 |
| Carvedilol | 233 | $2,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $423,628373 claims |
| Johnson & JohnsonXarelto | $73 | $142,942126 claims |
| NovartisEntresto | $36 | $142,732119 claims |
| AstraZenecaFarxiga, Brilinta | $4,795 | $46,94641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Clearwater
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.